vs
Side-by-side financial comparison of Nextpower Inc. (NXT) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Nextpower Inc. is the larger business by last-quarter revenue ($909.4M vs $699.9M, roughly 1.3× QuidelOrtho Corp). Nextpower Inc. runs the higher net margin — 14.4% vs -104.7%, a 119.2% gap on every dollar of revenue. On growth, Nextpower Inc. posted the faster year-over-year revenue change (33.9% vs -3.7%). Nextpower Inc. produced more free cash flow last quarter ($118.5M vs $-94.7M). Over the past eight quarters, Nextpower Inc.'s revenue compounded faster (11.1% CAGR vs -2.9%).
Nextpower Inc. (NXT) is a global energy technology provider based in Fremont, California.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
NXT vs QDEL — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $909.4M | $699.9M |
| Net Profit | $131.2M | $-733.0M |
| Gross Margin | 31.7% | — |
| Operating Margin | 19.4% | -100.7% |
| Net Margin | 14.4% | -104.7% |
| Revenue YoY | 33.9% | -3.7% |
| Net Profit YoY | 13.8% | -3583.4% |
| EPS (diluted) | $0.85 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $909.4M | — | ||
| Q3 25 | $905.3M | $699.9M | ||
| Q2 25 | $864.3M | $613.9M | ||
| Q1 25 | $924.3M | $692.8M | ||
| Q4 24 | $679.4M | $707.8M | ||
| Q3 24 | $635.6M | $727.1M | ||
| Q2 24 | $719.9M | $637.0M | ||
| Q1 24 | $736.5M | $711.0M |
| Q4 25 | $131.2M | — | ||
| Q3 25 | $146.9M | $-733.0M | ||
| Q2 25 | $157.2M | $-255.4M | ||
| Q1 25 | $156.8M | $-12.7M | ||
| Q4 24 | $115.3M | $-178.4M | ||
| Q3 24 | $115.4M | $-19.9M | ||
| Q2 24 | $121.7M | $-147.7M | ||
| Q1 24 | $205.2M | $-1.7B |
| Q4 25 | 31.7% | — | ||
| Q3 25 | 32.4% | — | ||
| Q2 25 | 32.6% | — | ||
| Q1 25 | 33.1% | — | ||
| Q4 24 | 35.5% | — | ||
| Q3 24 | 35.4% | — | ||
| Q2 24 | 33.0% | — | ||
| Q1 24 | 46.2% | — |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 20.0% | -100.7% | ||
| Q2 25 | 21.5% | -29.4% | ||
| Q1 25 | 21.1% | 4.7% | ||
| Q4 24 | 22.1% | -14.2% | ||
| Q3 24 | 21.0% | 2.1% | ||
| Q2 24 | 22.2% | -18.4% | ||
| Q1 24 | 36.8% | -247.3% |
| Q4 25 | 14.4% | — | ||
| Q3 25 | 16.2% | -104.7% | ||
| Q2 25 | 18.2% | -41.6% | ||
| Q1 25 | 17.0% | -1.8% | ||
| Q4 24 | 17.0% | -25.2% | ||
| Q3 24 | 18.2% | -2.7% | ||
| Q2 24 | 16.9% | -23.2% | ||
| Q1 24 | 27.9% | -239.9% |
| Q4 25 | $0.85 | — | ||
| Q3 25 | $0.97 | $-10.78 | ||
| Q2 25 | $1.04 | $-3.77 | ||
| Q1 25 | $1.05 | $-0.19 | ||
| Q4 24 | $0.79 | $-2.54 | ||
| Q3 24 | $0.79 | $-0.30 | ||
| Q2 24 | $0.84 | $-2.20 | ||
| Q1 24 | $1.52 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $952.6M | $98.1M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $2.2B | $2.0B |
| Total Assets | $3.8B | $5.7B |
| Debt / EquityLower = less leverage | — | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $952.6M | — | ||
| Q3 25 | $845.3M | $98.1M | ||
| Q2 25 | $743.4M | $151.7M | ||
| Q1 25 | $766.1M | $127.1M | ||
| Q4 24 | $693.5M | $98.3M | ||
| Q3 24 | $561.9M | $143.7M | ||
| Q2 24 | $471.9M | $107.0M | ||
| Q1 24 | $474.1M | $78.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.0B | $2.0B | ||
| Q2 25 | $1.8B | $2.8B | ||
| Q1 25 | $1.6B | $3.0B | ||
| Q4 24 | $1.4B | $3.0B | ||
| Q3 24 | $1.3B | $3.2B | ||
| Q2 24 | $1.1B | $3.2B | ||
| Q1 24 | $961.0M | $3.3B |
| Q4 25 | $3.8B | — | ||
| Q3 25 | $3.7B | $5.7B | ||
| Q2 25 | $3.4B | $6.4B | ||
| Q1 25 | $3.2B | $6.5B | ||
| Q4 24 | $3.0B | $6.4B | ||
| Q3 24 | $2.8B | $6.8B | ||
| Q2 24 | $2.6B | $6.7B | ||
| Q1 24 | $2.5B | $6.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.3M | $-45.5M |
| Free Cash FlowOCF − Capex | $118.5M | $-94.7M |
| FCF MarginFCF / Revenue | 13.0% | -13.5% |
| Capex IntensityCapex / Revenue | 0.5% | 7.0% |
| Cash ConversionOCF / Net Profit | 0.94× | — |
| TTM Free Cash FlowTrailing 4 quarters | $587.3M | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.3M | — | ||
| Q3 25 | $186.9M | $-45.5M | ||
| Q2 25 | $81.3M | $-46.8M | ||
| Q1 25 | $237.3M | $65.6M | ||
| Q4 24 | $143.8M | $63.7M | ||
| Q3 24 | $153.8M | $117.9M | ||
| Q2 24 | $120.8M | $-97.9M | ||
| Q1 24 | $111.5M | $-700.0K |
| Q4 25 | $118.5M | — | ||
| Q3 25 | $171.4M | $-94.7M | ||
| Q2 25 | $70.1M | $-84.3M | ||
| Q1 25 | $227.2M | $9.4M | ||
| Q4 24 | $134.9M | $16.5M | ||
| Q3 24 | $141.8M | $71.4M | ||
| Q2 24 | $118.0M | $-133.2M | ||
| Q1 24 | $109.2M | $-66.8M |
| Q4 25 | 13.0% | — | ||
| Q3 25 | 18.9% | -13.5% | ||
| Q2 25 | 8.1% | -13.7% | ||
| Q1 25 | 24.6% | 1.4% | ||
| Q4 24 | 19.9% | 2.3% | ||
| Q3 24 | 22.3% | 9.8% | ||
| Q2 24 | 16.4% | -20.9% | ||
| Q1 24 | 14.8% | -9.4% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 1.7% | 7.0% | ||
| Q2 25 | 1.3% | 6.1% | ||
| Q1 25 | 1.1% | 8.1% | ||
| Q4 24 | 1.3% | 6.7% | ||
| Q3 24 | 1.9% | 6.4% | ||
| Q2 24 | 0.4% | 5.5% | ||
| Q1 24 | 0.3% | 9.3% |
| Q4 25 | 0.94× | — | ||
| Q3 25 | 1.27× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 1.51× | — | ||
| Q4 24 | 1.25× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 0.99× | — | ||
| Q1 24 | 0.54× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NXT
| Transferred Over Time | $763.9M | 84% |
| Transferred At Point In Time | $145.4M | 16% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
